Comparative Pharmacology
Head-to-head clinical analysis: KLOXXADO versus NALTREXONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOXXADO versus NALTREXONE HYDROCHLORIDE.
KLOXXADO vs NALTREXONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Competitive antagonist at mu, kappa, and delta opioid receptors, with highest affinity for mu receptors. Also acts as an antagonist at the toll-like receptor 4 (TLR4).
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
50 mg orally once daily for opioid dependence; 25 mg orally once daily for alcohol dependence, may increase to 50 mg after one week.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Terminal elimination half-life: ~4 hours for naltrexone; its major active metabolite, 6-β-naltrexol, has a half-life of ~13 hours. The longer half-life of the metabolite contributes to sustained receptor blockade.
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Renal: primarily as unchanged drug (<2%) and metabolites (mainly 6-β-naltrexol, glucuronide conjugates); approximately 60% of dose excreted in urine (including metabolites) and about 30% in feces via biliary excretion.
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist